Abstract Background: Recent research has revealed that ferroptosis plays an important part in the pathophysiological process of numerous body systems, including the nervous system. Ferroptosis may be linked to the onset and progression of Alzheimer’s disease (AD). Objective: The goal of this study was to look at the serum levels of free iron, total iron-binding capacity (TIBC), ferritin, and divalent metal transporter 1 (DMT1) in Alzheimer’s patients. Materials and Methods: A total of 80 blood samples were taken from 40 cases of Alzheimer’s disease and 40 healthy controls for a case–control study. The following parameters’ regarding serum biomarker levels were determined: The serum DMT1 was measured using the enzyme-linked immunosorbent assay technique. The colorimetric approach is used for serum-free iron and TIBC, and the spectrophotometric method is used for serum ferritin. The receiver operating characteristic (ROC) curve was used to assess the accuracy of the prediction value. Results: When compared to healthy control groups, patients with Alzheimer’s disease had an increasing range level of TIBC, free iron, and ferritin, whereas the range level of DMT1 was lowered. ROC and area under curve analysis results for the ion forms were utilized as a feasible diagnostic parameter, and it was found that free iron and TIBC have an excellent diagnostic performance for Alzheimer’s disease prediction when compared to the control group. Conclusion: Changes in iron levels in Alzheimer’s disease patients should be addressed since homeostatic imbalance can have dual repercussions via iron induction. An imbalance in brain iron status can result in free radical production and oxidative damage, leading to neurodegenerative illness.
Al-Razaq et al. (Thu,) studied this question.